« Back to Medicines list

Minims Lidocaine & Fluorescein.

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 01/06/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 27/5/2020

Click on this link to Download PDF directly

Bausch Health Ireland Ltd.

Bausch & Lomb U

Company Products

Medicine NameActive Ingredients
Medicine Name Artelac, Eye drops solution Active Ingredients Hypromellose
Medicine Name Artelac, SDU, Eye drops solution Active Ingredients Hypromellose
Medicine Name Emerade, 150 micrograms, solution for injection in pre-filled pen Active Ingredients Adrenaline tartrate
Medicine Name Emerade, 300 micrograms, solution for injection in pre-filled pen Active Ingredients Adrenaline tartrate
Medicine Name Emerade, 500 micrograms, solution for injection in pre-filled pen Active Ingredients Adrenaline tartrate
Medicine Name GelTears, Eye Gel Active Ingredients Carbomer
Medicine Name Liposic 2mg/g Eye Gel Active Ingredients Carbomer
Medicine Name Lotemax 0.5% Eye Drops, Suspension Active Ingredients Loteprednol Etabonate
Medicine Name Megace 160mg Tablets Active Ingredients megestrol acetate
Medicine Name Megace 40mg/ml oral suspension Active Ingredients megestrol acetate
Medicine Name Minims Artificial Tears, Eye drops solution Active Ingredients Hyetellose, Sodium Chloride
Medicine Name Minims Atropine Sulphate 1%w/v, Eye drops solution Active Ingredients Atropine sulfate
Medicine Name Minims Chloramphenicol 0.5% w/v, Eye drops solution Active Ingredients Chloramphenicol
Medicine Name Minims Cyclopentolate Hydrochloride 1.0% w/v, Eye drops solution Active Ingredients Cyclopentolate Hydrochloride
Medicine Name Minims Fluorescein Sodium 1%, Eye drops solution Active Ingredients Fluorescein Sodium
Medicine Name Minims Fluorescein Sodium 2%, Eye drops solution Active Ingredients Fluorescein Sodium
Medicine Name Minims Lidocaine & Fluorescein. Active Ingredients Fluorescein Sodium, Lidocaine Hydrochloride
Medicine Name Minims Oxybuprocaine Hydrochloride 0.4% w/v eye drop solution Active Ingredients Oxybuprocaine Hydrochloride
Medicine Name Minims Phenylephrine Hydrochloride 2.5%, Eye drops solution Active Ingredients Phenylephrine Hydrochloride
Medicine Name Minims Pilocarpine Nitrate 2% w/v, Eye drops solution Active Ingredients Pilocarpine nitrate
Medicine Name Minims Povidone Iodine 5% w/v eye drops, solution Active Ingredients Povidone Iodine
Medicine Name Minims Prednisolone Sodium Phosphate 0.5% Active Ingredients Prednisolone Sodium Phosphate
Medicine Name Minims Proxymetacaine 0.5% w/v, Eye Drops Solution Active Ingredients Proxymetacaine hydrochloride
Medicine Name Minims Saline Active Ingredients Sodium Chloride
Medicine Name Minims Tetracaine Hydrochloride 0.5% w/v, Eye drops solution Active Ingredients Tetracaine hydrochloride
1 - 0 of 33 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 1 June 2020 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number
  • Change to section 6 - date of revision

Updated on 27 May 2020

Reasons for updating

  • New SmPC for medicines.ie

Updated on 29 July 2015 SPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 9 - Date of renewal of authorisation

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

change in marketing authorisation  holder and date of revision of text

Updated on 29 July 2015

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 28 July 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 28 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to marketing authorisation holder

Updated on 30 August 2012 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 24 July 2008 SPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.8 - Undesirable effects
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Sections 1, 2 and 3 : Change in the wording following renewal of the product

 

Sections 9 and 10 : Change in the dates following renewal

 

Section 4.8 : addition of undesirable effects: symptoms of allergic-type reactions and anaphylaxis

Updated on 29 August 2007 SPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

section 4.3
replacement of the following sentence
Do not use in patients with a known hypersensitivity to fluorescein or lidocaine and other amide-tye local anaesthetics.
 by:
Do not use in patients with a known hypersensitivity to either of the active ingredients.
 
section 4.4
replacement of the following paragraph
The anaesthetised eye should be protected from foreign body contamination, particularly in elderly patients in whom the duration of anaesthesia may exceed 30 minutes.
by:
The cornea may be damaged by prolonged application of anaesthetic eye drops.
 
The anaesthetised eye should be protected from dust and contamination.

Updated on 15 August 2005 SPC

Reasons for updating

  • Change from the BAN of the active substance to the rINN

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 11 August 2005 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 5 August 2005 SPC

Reasons for updating

  • Change from the BAN of the active substance to the rINN

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 16 May 2005 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 6.1 - List of excipients
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 21 August 2003 SPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 16 July 2003 SPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)